Welcome to our dedicated page for PARABILIS MEDICINES SEC filings (Ticker: PBLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARABILIS MEDICINES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARABILIS MEDICINES's regulatory disclosures and financial reporting.
Parabilis Medicines, Inc. disclosed that investment vehicles managed by RA Capital made substantial purchases and conversions into its Voting Common Stock. On June 11, 2026, RA Capital–related funds completed open‑market purchases totaling 21,188,750 shares of Voting Common Stock at $20.00 per share, held indirectly through the funds. On the same date, Series E and Series F Preferred Stock automatically converted into additional Voting Common Stock immediately prior to the closing of the IPO, with Series E converting at a 1 to 0.6524 ratio and Series F at a 1 to 0.6498 ratio, without payment of consideration. The RA Capital adviser and related entities disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Parabilis Medicines director Edward M. Fitzgerald reported a series of non-cash conversions of preferred stock into common shares. On June 11, 2026, he converted Series B, C and F Preferred Stock into Common Stock, acquiring 5,539, 3,878 and 5,271 common shares, respectively, at $0.00 per share.
These preferred shares automatically converted into common immediately prior to the closing of the company’s initial public offering on June 9, 2026, as described in the footnotes. No shares were sold; all Form 4 transactions are coded as conversions of derivative securities. Following these transactions, Fitzgerald directly holds 14,688 shares of Common Stock.
Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026. The shares are held indirectly, with Alan Sebulsky disclaiming beneficial ownership except for any pecuniary interest.
Parabilis Medicines director Alexis Borisy converted preferred stock into common shares tied to the company’s IPO. On June 11, 2026, 162,221 shares of Series F Preferred Stock were converted into 105,414 shares of Common Stock, leaving him with 105,414 common shares directly owned. According to the terms, each preferred share converted at a 1 to 0.6498 rate and automatically converted into common shares immediately before the closing of the initial public offering on June 9, 2026. This was a non-cash derivative conversion, not an open‑market purchase or sale.
Parabilis Medicines, Inc. reported that investment funds managed by Deerfield converted multiple series of preferred stock into voting common stock in connection with the company’s initial public offering. The Form 4 shows Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P. acquiring an aggregate of 2,042,004 shares of voting common stock through automatic conversions coded as “C” transactions, all at a stated price of $0.00 per share. After these conversions, the preferred stock positions reported for Series A, B, C and D show zero remaining shares, indicating full conversion into common. The filing states that the Deerfield-affiliated reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Parabilis Medicines, Inc. reported that RA Capital–affiliated reporting persons filed a Form 4 for a compensation-related stock option grant linked to its common stock. The derivative award covers 20,215 shares of common stock at an exercise price of $20.00 per share and was granted at no cost.
The option vests in full on the earlier of June 9, 2027 or the date of Parabilis’ next annual stockholder meeting, subject to Dr. Simson’s continued service on that vesting date, and expires on June 8, 2036. Footnotes explain that under Dr. Simson’s arrangement with RA Capital’s investment adviser, the option is held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P., and net proceeds from any exercise will offset advisory fees, with all reporting persons disclaiming beneficial ownership except for any pecuniary interest.
Parabilis Medicines, Inc. director Alexis Borisy received a grant of stock options covering 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036.
These options vest and become exercisable in full on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, subject to Borisy’s continued service. Following this grant, Borisy holds 20,215 stock options directly, according to the filing.
Parabilis Medicines director Barbara Weber received a grant of stock options for 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, subject to her continued service.
Parabilis Medicines director Yeshwant Krishna received a grant of stock options as compensation. The award covers 20,215 options to buy common stock at an exercise price of $20.00 per share, expiring on June 8, 2036. These options vest and become exercisable in full on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, contingent on his continued service. After this grant, he holds 20,215 derivative securities directly.
Parabilis Medicines, Inc. director Edward M. Fitzgerald received a grant of stock options covering 20,215 shares of common stock. The options have an exercise price of $20.0000 per share and expire on June 8, 2036. The underlying 20,215 shares will vest and become exercisable in full on the earlier of June 9, 2027 or the date of the issuer's next annual meeting of stockholders, subject to his continued service on that vesting date.